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INTRODUCTION AND AIM 
The aim of this study was to investigate the outcome of a paediatric onset of inflammatory bowel 
disease (IBD) in a cohort of subjects with primary sclerosing cholangitis (PSC) and in a matched-age 
population-based control group without PSC.  
METHODS 
We identified 28 IBD-PSC cases (median age at IBD diagnosis 12.5 years, 25-75th: 10-16 years) and 
selected three IBD controls for each case matched for age and year of IBD diagnosis. All data 
regarding the gastrointestinal tract and liver were collected at diagnosis and at last follow-up (median 
15 years). 
RESULTS 
At diagnosis the prevalence of pancolitis was similar between the groups (78% and 79%, respectively 
p= 0.30), but histologic inflammation was milder in IBD-PSC (61% vs 30%, p= 0.06). At last follow-
up (median age 29 years) pancolitis was less frequent (6% and 33%, respectively p=0.04) and the 
remission higher (76% and 47%, respectively p=0.08) in IBD-PSC patients than in IBD patients. 
Panproctolectomy (32% in IBD-PSC and 34% in IBD, p=1.0) and the rate of pouchitis (62% and 
70%, respectively p= 0.8) were similar.   
CONCLUSIONS 
The outcome of paediatric onset IBD in patients with PSC in adulthood seems to be comparable to 
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Primary sclerosing cholangitis (PSC) is an inflammatory and fibrotic disease characterised by 
strictures and dilatations, involving both the intra- and extra-hepatic bile ducts 1.  
The disease affects mostly males around the age of 34-40 years 1, but it may also occur  in children. 
In childhood, 30-50% of patients present a unique phenotype characterised by an overlap with 
autoimmune hepatitis (AIH), i.e., elevation of transaminases, positive autoantibodies, interface 
hepatitis in liver biopsy, and they are so referred to as having autoimmune sclerosing cholangitis 
(ASC) or PSC-AIH overlap syndrome 2.  
The aetiology of PSC in children and in adults is unknown, but an interaction between a genetic 
predisposition 3-5 and environmental factors 6 has been proposed. The disease is associated in the 
majority of the patients with inflammatory bowel disease (IBD), with ulcerative colitis (UC) being 
the most common form and less frequently Crohn´s disease (CD) and unclassified-colitis (IBD-U) 7. 
In adults IBD associated with PSC (IBD-PSC) might present a different genetic profile 8. Still, IBD-
PSC presents a unique phenotype, characterised by mild inflammation, rectal sparing, backwash 
ileitis and a higher risk of colon-rectal cancer. 9.  However, data on the clinical course and prognosis 
of IBD in patients with a paediatric onset IBD-PSC are underreported and conflicting (Supplement 
1).  
Thus, this study was aimed at comparing the clinical course and follow-up of IBD in a cohort of 
patients with a paediatric onset of IBD-PSC and in a population-based group of patients with a 





This is an observational longitudinal retrospective case-control population-based study. 
Study area, population and time. 
Helsinki University Hospital (HUH) is a Tertiary Referral Centre in Finland (overall population about 
5.6 million inhabitants), serving a defined population of about 1.5 million inhabitants and covering 
approximately 30% of the total child population in the country (www.stat.fi). Most paediatric and 
adult patients with PSC are referred from all over the country to this centre for diagnosis and the 
follow-up of the disease. 
We identified 28 patients with a diagnosis of IBD-PSC in childhood or during adolescence (< 20 
years; diagnosed between 1989 and 2011) 10.  
For each IBD-PSC case, three IBD controls matched for age and year of IBD diagnosis were selected 
from the IBD Study Registry at HUH. Since the majority of children with PSC presented with UC or 
IBD-U (26/28, 93%) and the two patients with CD had pancolitis, only controls with UC/IBD-U were 
selected. 
PSC-ascertainment  
All medical records were reviewed to ensure the correct diagnosis. 
Diagnosis of PSC was based on: 1. elevation of liver enzymes (i.e., gamma glutamyltranspeptidase 
and/or alkaline phosphatase and alanine aminotransferase), 2. typical cholangiographic features of 
the disease (i.e., strictures and dilations involving both intra- and/or extra-hepatic bile ducts) obtained 
by endoscopic retrograde cholangiography (ERC), 3. histologic features in the liver biopsy 
compatible with PSC or PSC-AIH and 4. other imaging techniques suggestive of PSC (i.e., magnetic 
resonance imaging). In this respect, all liver biopsies were reviewed by an experienced pathologist 
blinded for the patients’ outcome. Patients fulfilling the diagnostic criteria for both PSC and AIH 10 
were diagnosed as having PSC-AIH; the modified diagnostic score for AIH proposed by the IAIHG 
in 1999 11 was retrospectively applied to the patients to ensure the diagnosis of PSC-AIH 10.  
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Patients affected by secondary sclerosing cholangitis, as well as by other liver diseases (i.e., genetic, 
viral and/or metabolic), were excluded.  
IBD-ascertainment  
The disease extent at diagnosis of IBD and at the last follow-up were reviewed according to the Paris 
Classification of Ulcerative Colitis criteria 12. In detail, disease extent (i.e., E1: distal proctitis, E2: 
left-sided colitis, E3: extensive colitis, E4: pancolitis) and severity (i.e., S0: Prednisolone/Prednisone 
never used and S1: Prednisolone/Prednisone used at least once during the follow-up) were collected.  
Similarly, the following histological features in colonoscopy were collected: location of 
inflammation, the type of inflammation (absence/inactive or active), the degree of active 
inflammation (i.e., mild, moderate, severe) and the localisation and degree (i.e., mild or severe) of 
dysplasia.  
Medications (i.e., glucorticosteroids, 5-aminosalicylic acid or 5-ASA, thiopurine, TNF-alfa 
inhibitors) and surgery (i.e., time and type of surgery and eventually any complications such as 
pouchitis) were also collected.  
Follow-up 
For the study purpose, follow-up was considered to start when the patient was referred to HUH for 
the diagnosis of IBD and ended by the index date 01.09.2018.  
Statistical analysis  
Data are presented as number with percentage when categorical and as median with 25-75 percentiles 
when continuous. Differences were tested by using Fisher´s Exact Test or the Chi-Square Test for 
categorical and Mann-Whitney Test for continuous variables. p was considered statistically 
significant when < 0.05.  
Ethics 




Baseline characteristics of IBD-PSC cases and IBD-controls. 
Twenty-eight IBD-PSC patients (birth dates between 1976-2001) with a median age at IBD diagnosis 
of 12.5 years and median age at PSC diagnosis of 15 years were included. Eighteen children (64%) 
had PSC, and 10 (36%) were PSC-AIH; no cases of isolated small duct PSC were seen.  Eighty-four 
matched IBD-controls were eligible (median age at IBD diagnosis 12 years) (Table 1). Baseline 
characteristics of PSC cases with and without AIH are reported in Supplement 2.  
Last follow-up 
The median length of follow-up was 14 years (25-75th: 10.0-19.7) in the IBD-PSC group and 15 years 
(25-75th: 11.0-19.0) in the IBD-controls. At the end of follow-up, the median age was 29.0 years in 
the IBD-PSC group (25-75th: 22.5-33.7) and 28.0 years (25-75th: 23-31.0) in the IBD controls. We 
found no statistically significant differences between the two groups (Table 1). Baseline 
characteristics of PSC cases with and without AIH are reported in Supplement 2.  
Endoscopic location of IBD and disease severity at diagnosis and last follow-up according to the 
Paris Classification Criteria. 
Data concerning disease extent and severity in IBD-PSC cases and IBD-controls are summarised in 
Table 2.  
We did not find any statistically significant difference in endoscopic disease extent at IBD diagnosis 
(p= 0.30). At diagnosis, most patients had pancolitis (IBD-PSC 78% and IBD 79%). Backwash ileitis 
was detected in two patients with IBD-PSC and in two with IBD respectively, and rectal sparing was 
seen in one patient with IBD-PSC. 
However, at the last follow-up the endoscopic remission rate was higher in the IBD-PSC than in the 
IBD-control group (75% vs 47%), the difference being close to statistical significance (p= 0.08) 
(Figure 1). Pancolitis (i.e. E4) was more frequent in the IBD-control than in the IBD-PSC group (33% 
vs. 6 %; p= 0.04).  
Histological inflammation at diagnosis and last follow-up. 
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Data on histological findings are summarised in Table 3. All the patients had active colitis at 
diagnosis. Three IBD-PSC cases also had inflammation in the terminal ileum and one in the colon 
with rectal sparing. Among IBD-cases, inflammation involved the rectum only in 3, the left-side in 
4, up to the hepatic flexure in 4; ten patients also had inflammation in the terminal ileum. We found 
a statistically significant difference in the degree of histologic inflammation at time of diagnosis 
between IBD-PSC cases and IBD controls, with IBD-PSC patients having more frequently 
inflammation graded as mild (61% vs 30%, p= 0.006) (Figure 2) and IBD patients more frequently 
graded as severe (35% vs 8%, p= 0.006). No cases of dysplasia or cancer were detected at IBD 
diagnosis. 
We did not find any statistically significant difference between IBD-PSC cases and IBD-controls for 
the presence and degree of inflammation at the last follow-up, although inflammation tended to be 
graded more frequently as mild among IBD-PSC cases (62 vs 31%, p= 0.08).  
One 26-year old IBD-PSC patient developed low-grade dysplasia in the colon and underwent a 
panproctocolectomy with a J-pouch. We found no cases of adenocarcinoma in the colon. 
Medical treatment during the follow-up and at last follow-up 
During follow-up, 5 IBD-PSC patients (classified as PSC-AIH) had used glucocorticosteroids and 
thiopurine for their liver disease. The other patients on these drugs had their intestinal disease as an 
indication (Supplement 3). IBD controls had more frequently used glucocortiosteroids at least once 
than the IBD-PSC group (84% vs 64%, p=0.03). Still, the number of IBD-controls on TNF-alpha 
inhibitors during follow-up was higher, although not statistically significant (28% vs 14%, p=0.20).  
We found a statistically significant difference in disease severity (overall use of glucocorticosteroids) 
at the last follow-up between IBD-PSC cases and IBD-controls (p= 0.03) (Supplement 3).  
Surgery during follow-up. 
Data on surgery are summarised in Supplement 4 and 5. We found no statistically significant 
difference in the number of panprocto-colectomies between IBD-PSC cases (9/28; 32%) and IBD-
controls (31/84; 34%, p=1.0). Among IBD-PSC cases, a J-pouch was performed in eight 8/9 (89%) 
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and ileostomy in one. Among IBD-controls, a J-pouch was performed in 27 (87%), but in two cases, 
it was followed by ileostomy because of severe pouchitis; ileostomy was performed as first treatment 
in two. The rate of pouchitis (5/8, 62% vs 19/27, 70%, p= 0.8) and recurrent pouchitis (4/5, 80% vs 
15/19, 79%, p= 1.0) was similar between the groups. Twenty-four IBD-PSC patients (86%) received 
repeatedly metronidazole for prevention of cholangitis. The 19 IBD controls with pouchitis received 
metronidazole and/or ciprofloxacin, one patient received stool transplantation and two were operated 
on with ileostomy. Among IBD-PSC cases, extra-intestinal surgery was performed in four: two 
patients underwent liver transplantation (repeatedly confirmed dysplasia and aneuploidy in one and 
progressive increment of Ca 19-9 with cirrhosis in one), one splenectomy for autoimmune 
thrombocytopenia and one cholecystectomy for lithiasis. 
 
DISCUSSION 
Statement of principal findings. The clinical course and outcome of IBD in children with PSC is 
underreported in the literature 13. To our knowledge, this is the first case-control population-based 
study in Europe reporting a long-term follow-up (median 15 years) until adulthood of a paediatric 
onset IBD between two groups of patients, i.e., with and without PSC.  
The main findings of this study are: 1. At diagnosis, children with IBD-PSC and IBD had comparable 
disease extent (i.e., mostly pancolitis), but patients with IBD-PSC were more often in remission and 
had less pancolitis after a median follow-up of 15 years, 2. At diagnosis and during follow-up IBD-
PSC children had mild histological inflammation, 3. Colon dysplasia was detected in one patient with 
IBD-PSC, 4. Medical treatment and need for surgery were comparable between children with IBD-
PSC and IBD 5. IBD-PSC patients with a J-pouch had the same rate of pouchitis than patients with 
IBD.  
Disease location and severity. IBD-PSC and PSC patients had the same rate of pancolitis at 
diagnosis, which is in contrast with the current literature. However, IBD-PSC patients tended to have 
a higher remission rate and less pancolitis than IBD patients at a median follow-up of 15 years.  
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A recent meta-analysis in children has reported an association between IBD-PSC and pancolitis (RR 
1.42; 95%CI: 1.22-1.64) 13. At diagnosis of IBD, Ordonez et al. has found a higher rate of pancolitis 
in children with IBD also associated with autoimmune disease other than PSC (i.e., PSC-AIH, AIH, 
coeliac disease and hypereosinophilic syndrome) 14. Lascurain et al. and Shiau et al. reported that 
pancolitis was more common in children with IBD-PSC then in those with only IBD (90% vs 72% 
and 96% vs 64%, respectively) 15, 16. The same meta-analysis has shown an association between IBD-
PSC and rectal sparing (RR 3.91; 95%CI: 1.31-11.62), but not with backwash ileitis (RR 2.43; 
95%CI: 0.86-6.89). In adults, IBD-PSC may present a unique phenotype characterised by mild 
inflammation with a right side predominance and a pancolonic involvement associated to  backwash 
ileitis and a rectal sparing 9. In our study, backwash ileitis and rectal sparing were rare. This is in line 
with previous reports as rectal sparing has been detected in only 7-26% of the children, querying the 
“unique IBD phenotype” in the paediatric population 14, 15, 17.  
Histology and dysplasia. In IBD-PSC children, inflammation was mostly mild at diagnosis and at 
the last follow-up. To our knowledge, this is the first population-based study comparing histologic 
characteristics of intestinal inflammation between children with IBD-PSC and only IBD. A similar 
result was reported in adults 18. In a retrospective series, Faubion et al. found a mild-moderate degree 
of inflammation in 83% of children with IBD-PSC 17, which is similar to our rate of 92%. Recently, 
Ricciuto et al. has shown in a prospective study including 87 children with colitis that children with 
PSC in clinical remission have more subclinical inflammation that in turn might play a role in the 
development of colorectal cancer 19. PSC is a risk factor for colorectal cancer in IBD. In a Dutch 
population-based study, patients with IBD-PSC had a 10-fold increased risk of colon-rectal cancer 
compare to UC-controls 20. However, the risk in a paediatric onset IBD-PSC is still unclear. None of 
the studies on the clinical course and prognosis of a paediatric onset PSC 10, 21-25 reported any case of 
colorectal cancer/dysplasia during a median follow-up of 4-9 years. Among the studies conducted on 
the clinical course and prognosis of a paediatric onset IBD-PSC 14-17, only Faubion et al reported three 
cases of dysplasia in the colon (17, 23, 32-year-olds at 4 months, 10 years and 22 years after IBD 
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diagnosis) 17. In our study, one patient with IBD-PSC developed low-grade dysplasia at the age of 26 
years, after 10 years from IBD diagnosis. In our centre, all PSC patients receive ursodeoxycholic acid 
at low dosage (15 mg/Kg), which in some studies has been reported to reduce the inflammation in the 
colon 26 and the risk of colon cancer in patients with IBD-PSC 27. However, this result needs what the 
current guidelines recommend - to perform a screening ileocolonscopy at the time of PSC diagnosis 
and then every year in patients with IBD-PSC 28, 29. However, the right policy is still unclear in 
children and adolescents, since ileocolonscopy is an invasive procedure, needing deep sedation. 
Further multi-centre prospective studies are needed in the future to fill this important gap. However, 
we believe that annual colonoscopies are not needed in young children when in remission (i.e. low 
fecal calprotectin) as ongoing inflammation is the major risk factor for adenocarcinoma 30, 31. In the 
above-mentioned study, Ricciuto et al also showed that fecal calprotectin with a value < 100 mcg/g 
performed better than the symptom-based clinical activity index in detecting mucosal healing in 
children with IBD-PSC 19.  
Medical treatment. During the follow-up, patients with IBD had more frequently used 
glucocorticosteroids. This finding might suggest a more benign course of IBD in patients with IBD-
PSC. Turunen et al has reported a more aggressive course of IBD in children then in adults with about 
80% of the paediatric patients needing glucocorticoids at some point of the follow-up 32. Shiau et al. 
found less use of steroids and TNF-alfa inhibitors in children with IBD-PSC 16. However, we did not 
find any difference in the use of 5-ASA compounds, thiopurine and TNF-alfa inhibitors.  Notably, it 
is challenging to draw conclusions on the effect of medical treatment in patients with IBD-PSC, since 
many of them have an overlap with AIH, hampering the assessment of indications in a retrospective 
study to differentiate whether the glucocorticoids/immunosuppressors were used for liver disease or 
for intestinal disease. 
Surgical treatment. During the follow-up, patients with IBD-PSC and IBD had similar numbers of 
panproctolecotmies with J-pouch reconstructions; ileostomy was seldom performed in both groups. 
Lascurain et al. reported a higher number of colectomies in IBD-PSC patients than in IBD-controls, 
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although the difference was not statistically significant 15. The same study group has also reported 
autoimmune liver disease as a risk factor for colectomy 15, however,  this was not the case in our 
study, although we had a similar rate of AIH overlap syndrome study (36% vs 33%) and a longer 
follow-up.  
Pouchitis is a frequent finding, and the rates of pouchitis and recurrent pouchitis were similar in 
patients with IBD-PSC and IBD during the median 12-year follow-up after surgery. Faubion et al 
reported at least one episode of pouchitis in four out of five patients with a paediatric onset IBD-PSC 
after 1.5 year from colectomy 17. Lascurain et al more recently reported that the rate of pouchitis was 
100% in IBD-PSC group and 64% in IBD-controls at 5 year follow-up 15. Penna et al. has reported a 
higher rate of pouchitis after colectomy and pouch-anal anastomosis in adult patients with IBD-PSC 
33. The majority of the IBD-PSC patients in our study received metronidazole since, as previously 
reported, metronidazole with ursodeoxycholic acid improve alkaline phosphatase level and Mayo 
score in patients with PSC 34. We speculate that the cyclic use of metronidazole might affect the risk 
of pouchitis in patients with IBD-PSC, but further multi-centre prospective studies are needed in the 
future to investigate the risk of pouchitis in larger cohorts of patients with paediatric onset IBD-PSC.  
Conclusions. The phenotypes of IBD in children and adolescents with IBD-PSC and IBD only are 
indistinguishable at diagnosis as both mostly present as pancolitis. Patients with IBD-PSC seem to 
have milder histological inflammation, need treatment with glucocorticoids less frequently and 
achieve remission more often during 15-years follow-up. The need for surgery and rate of pouchitis, 
however, is similar between patients with a paediatric onset IBD-PSC and IBD. Taken together, these 
findings suggest a comparable course of IBD in children with IBD-PSC. However, colon dysplasia 
may occur, necessitating surveillance of inflammation along the disease course, but to define the 
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Table 1. Baseline characteristics of IBD-PSC cases and IBD-controls. 
 IBD-PSC cases IBD controls p 
Number  28 84 - 
PSC-AIH 10 (36%) - - 
Males 19 (68%) 39 (46%) 0.06 
Median age and 25-75th percentiles at IBD diagnosis in years 12.5, 10-16 12, 10-15  0.4 
Median age and 25-75th percentiles at PSC diagnosis in 
years 
15, 12-17  - - 
Median age and 25-75th percentiles at last follow-up in years 29, 22-34  28, 23-31  0.4 
Median follow-up duration and 25-75th percentiles in years 14, 10-19.7 15, 11-19 0.8 
PSC: primary sclerosing cholangitis, IBD: inflammatory bowel disease. AIH: autoimmune hepatitis. 

























Table 2. Endoscopic location of IBD and disease severity at diagnosis and last-follow-up in IBD-
PSC cases and IBD-controls according to the Paris Classification of Ulcerative Colitis criteria 
(12). 









Extent of disease 
Not available  1/28 (4%) 1/84 (1%) 4/28 (14%) 6/84 (7%) 
J-pouch surgery/ileostomy - - 8/28 (28%) 29/84 (34%) 
Normal 2/27 (7%) 1/83 (1%) 12/16 (76%) 23/49 (47%)§ 
E1  0/27 (0%) 4/83 (5%) 1/16 (6%) 7/49 (14%) 
E2 3/27 (11%) 6/83 (7%) 2/16 (12%) 2/49 (4%) 
E3 1/27 (4%) 6/83 (7%) 0/16 (0%) 1/49 (2%) 
E4 21/27 (78%) 66/83 (79%) 1/16 (6%) 16/49 (33%)* 
Severity of disease 
Not available - - 0 (0%) 2 (1%) 
S0 - - 10/28 (36%) 13/83 (16%) 
S1 - - 18/28 (64%)* 69/83 (83%)* 
PSC: primary sclerosing cholangitis, IBD: inflammatory bowel disease.  
E1: distal proctitis, E2: left-sided colitis, E3: extensive colitis, E4: pancolitis.  
S0: Prednisolone/Prednisone never used, S1: Prednisolone/Prednisone used at least once during the 
follow-up. 
§p= 0.08, *p < 0.05. Fisher Exact Test and global Chi-Square Test were used when appropriate.  
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Table 3. Histological inflammation at diagnosis and last-follow-up in IBD-PSC cases and IBD-
controls. 









Not available 2/28 (7%) 2/84 (2%) 3/28 (11%) 3/84 (4%) 
J-pouch surgery/ileostomy - - 8/28 (28%) 29/84 (34%) 































PSC: primary sclerosing cholangitis, IBD: inflammatory bowel disease.  










Figure 1. Rate of endoscopic remission and pancolitis (E4) at last follow-up in PSC-IBD cases 
and IBD-controls. 
 




























































Figure 2. Rate of mild and severe inflammation on histology at diagnosis in PSC-IBD cases and 
IBD-controls. 
 

























































Rate of mild and severe inflammation on histology at diagnosis
p= 0.006
 (%)
p= 0.006
